Molnupiravir 200 mg

Molnovir 200 mg is an oral antiviral drug for emergency treatment of mild to moderate Covid-19 patients. U.S. FDA approved for emergency treatment of adult patients infected with the SARS-CoV-2 (COVID-19) virus and at risk for severe progression.

Using Molnovir to treat patients with COVID-19 showed significant clinical outcomes including:

• The first oral antiviral drug that is directly effective in attenuating viral RNA and SARS-CoV-2 in the nasopharynx.
• Convenient short-term treatment (5 days).
• Decreases the risk of hospitalization and mortality in adult patients suffering from mild-to-moderate COVID-19.
• Reduces patient’s risks of receiving mechanical ventilation.
• Effective against SARS-CoV-2 variants.
• Safe and well-tolerated.